Diltiazem atrial fibrillation
Pro Research Analysisby 
Searched over 200M research papers
Diltiazem for Atrial Fibrillation: Efficacy and Safety
Introduction to Diltiazem in Atrial Fibrillation Management
Atrial fibrillation (AF) is a common cardiac arrhythmia characterized by rapid and irregular beating. Diltiazem, a calcium channel blocker, is frequently used to manage AF, particularly in controlling the ventricular rate. This article synthesizes research findings on the efficacy and safety of diltiazem in treating AF.
Efficacy of Intravenous Diltiazem in Atrial Fibrillation
Rapid Rate Control in Emergency Settings
Several studies have demonstrated the effectiveness of intravenous diltiazem in rapidly controlling heart rate in patients with AF. In a multicenter, randomized, double-blind, placebo-controlled study, 95% of patients responded to diltiazem, compared to 0% for placebo, with a significant reduction in heart rate observed within minutes of administration . Another study comparing diltiazem to metoprolol found that diltiazem was more effective in achieving the target heart rate within 5 minutes and maintained this control over 30 minutes .
Continuous Infusion for Sustained Control
For sustained heart rate control, continuous infusion of diltiazem has also proven effective. In a study involving a 24-hour continuous infusion, 74% of patients maintained a therapeutic response compared to none in the placebo group . This suggests that diltiazem can provide both rapid and sustained rate control in AF patients.
Comparative Efficacy: Diltiazem vs. Other Agents
Diltiazem vs. Metoprolol
Meta-analyses and direct comparisons have shown that diltiazem is generally more effective than metoprolol in achieving rapid rate control in AF patients. A systematic review and meta-analysis revealed that diltiazem had a higher success rate in controlling heart rate compared to metoprolol, with no significant difference in the risk of hypotension between the two drugs . However, diltiazem was associated with a higher incidence of bradycardia .
Diltiazem vs. Digoxin
When compared to digoxin, diltiazem has shown superior efficacy in the emergency management of AF. Diltiazem achieved significant heart rate reduction within 5 minutes, whereas digoxin took up to 3 hours to show a similar effect . Additionally, in post-coronary artery bypass surgery patients, diltiazem provided faster ventricular rate control compared to digoxin, although long-term outcomes were similar .
Safety Profile of Diltiazem
Hypotension and Bradycardia
While diltiazem is effective in rate control, it is not without side effects. The incidence of hypotension is comparable to other rate control agents like metoprolol . However, diltiazem has a higher risk of causing bradycardia, which necessitates careful monitoring during administration .
Long-term Safety
Long-term safety data for diltiazem in AF patients are limited, and high-quality randomized studies are needed to fully assess its long-term safety and effectiveness . In the context of postoperative care, diltiazem did not significantly reduce the incidence of new-onset AF or 30-day mortality but was associated with bradycardia and increased norepinephrine requirements .
Conclusion
Diltiazem is a highly effective agent for rapid and sustained rate control in atrial fibrillation, particularly in emergency settings. It outperforms metoprolol and digoxin in terms of rapid rate control but carries a higher risk of bradycardia. While it is generally safe, careful monitoring is essential to manage potential side effects. Further research is needed to establish its long-term safety profile.
Sources and full results
Most relevant research papers on this topic